Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone

Phase 3 Completed 200 enrolled JW Pharmaceutical

RandomizedParallel-groupTriple-blindTreatment

Summary

This trial is to evaluate the efficacy and safety of CWP-0403 compared to Sitagliptin by proving non-inferiority in patients with type 2 Diabetes Mellitus insufficiently controlled with metformin alone.

Timeline

Start: 2011-05
Primary completion: 2013-05
Completion: 2013-10

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anagliptin	Small molecule	100 mg	—
Comparator	Sitagliptin	Small molecule	100 mg	—

Efficacy and Safety of CWP-0403 Compared to Sitagliptin in Patients With Type 2 Diabetes Mellitus Insufficiently Controlled With Metformin Alone

Summary

Timeline

Drugs

Indications